What does the Celltrion entry mean for Vietnam?
Celltrion launched Remsima (infliximab biosimilar) and Herzuma (trastuzumab biosimilar) in Vietnam in 2024-25, targeting autoimmune disease and breast/stomach cancer [Celltrion 2025; Medpath 2025]. Truxima (rituximab biosimilar) and Remsima SC are next in the Vietnam regulatory queue. Celltrion's portfolio gives Vietnam access to first-wave-mature monoclonal-antibody biosimilars with proven ex-Vietnam reference data.
Who are the domestic biosimilar developers?
Nanogen's Stimus (darbepoetin alfa biosimilar) is in late-stage clinical trials at multiple Vietnamese hospitals for anemia in chronic kidney disease and chemotherapy patients [Nanogen 2025]. Domestic biosimilar capacity remains thin compared to South Korea (Celltrion, Samsung Bioepis) or India (Dr. Reddy's, Biocon); the realistic 2027-30 picture is import-dominant supply with selective local manufacturing partnerships.
How does BHYT tender function as the demand pump?
The 2025 price-negotiation list expands biologics coverage [Binh Phuoc DOH 2025]. Trastuzumab biosimilars price at ~80% of Herceptin's reference brand [InsightAce 2025]; trastuzumab + bevacizumab + rituximab biosimilars typically achieve 50-70% ASP discounts versus reference biologics [InsightAce 2025]. For BHYT, the math compels switching as biosimilar reference standards reach equivalence parity.
Methodology note: Biosimilar launch and approval data sourced from Celltrion's Vietnam press materials [Celltrion 2025], Nanogen's clinical trial bulletin [Nanogen 2025], and Medpath's biopharma market coverage [Medpath 2025]. ASP discount ranges (50–70%) are sourced from InsightAce's trastuzumab biosimilar analysis [InsightAce 2025]. Biosimilar penetration estimate (single-digit % of biologics layer) is a KIRA in-house triangulation [Kira estimates]. The biopharmaceutical pool figure (~USD 7.3 bn) is from Medpath's Vietnam biopharma report [Medpath 2025]. Forecasts reflect KIRA's analyst view as of May 2026. No part of this article constitutes investment advice.